Clinical Trials Browser

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT02875223 2025-04-20

A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Phase 1 Terminated

75 enrolled 35 charts

Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms

NCT03724890 2025-04-10

Study of Avelumab-M3814 Combinations

Phase 1 Completed

57 enrolled 56 charts

Tumor-Agnostic

Neoplasms

NCT02783300 2025-03-10

Meteor 1

Phase 1 Completed

297 enrolled 76 charts

DermatologicGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Lymphoma, Non-Hodgkin, Melanoma, Neoplasms, Urologic Neoplasms

NCT02834390 2025-03-05

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 1 Completed

7 enrolled 16 charts

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT01214616 2025-02-07

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

Phase 1 Completed

17 enrolled 15 charts

Tumor-Agnostic

Neoplasms

NCT03447470 2025-01-29

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Phase 1 Completed

46 enrolled 29 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasms, Thymus Neoplasms

NCT03948763 2025-01-28

V941-001

Phase 1 Terminated

70 enrolled 18 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Phase 1 Terminated

44 enrolled 22 charts 1 FDA

CNSLymphoid

Lymphoma, Neoplasms, Neuroblastoma

NCT01946789 2025-01-22

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Phase 1 Completed

26 enrolled 22 charts

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Phase 1 Terminated

3 enrolled 10 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Phase 1 Completed

829 enrolled 100 charts

Tumor-Agnostic

Neoplasms

NCT04526509 2024-11-26

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Phase 1 Terminated

12 enrolled 12 charts

Sarcoma

Neoplasms, Liposarcoma, Myxoid

NCT02972034 2024-11-21

MK-8353-013

Phase 1 Terminated

111 enrolled 30 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

Clinical Trials

PanRAF

BOOST

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

A Study of LY3039478 in Participants With Advanced Cancer

Phase 1 Study of E7090 in Subjects With Solid Tumor

Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

KEYVIBE-001

A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

Dose Finding Study of BI 836880 in Patients With Solid Tumors

Weekly BI 836880 in Patients With Advanced Solid Tumors

Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours

Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Phase I Trial of BI 836845 for Various Solid Cancer

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

DEHART

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

HUMC 1612: Optune NovoTTF-200A System

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

MK-4280-001

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Study of Avelumab-M3814 Combinations

Meteor 1

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

V941-001

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

MK-8353-013